Neurodermatitis
Methodology & AI Transparency ⓘ
Neurodermatitis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Dermatology: Acne, Eczema, Psoriasis & Rosacea practice, Neurodermatitis (ICD-10 L28.0) is stratified through contact/systemic trigger review [Neurodermatitis L28.0], pairing targeted symptom control with longitudinal Affected Body Surface in Neurodermatitis (L28.0: Area (BSA /) surveillance.
- 2 Real-world patient consensus: Federal ICD-10-CM code L28.0 categorizes Neurodermatitis under Dermatology: Acne, Eczema, Psoriasis & Rosacea.
- 3 Typical cash cost range: Clinicians assessing Neurodermatitis focus on keratinocyte hyperproliferation [Neurodermatitis L28.0] and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Neurodermatitis: 25-Hydroxy Vitamin D in Neurodermatitis (L28.0: & hs-CRP) (25(OH)D 40–65 ng/mL (L28.0)) and Affected Body Surface in Neurodermatitis (L28.0: Area (BSA /).
Ask our AI Specialists anything about Neurodermatitis
What Is Neurodermatitis?
Within Dermatology: Acne, Eczema, Psoriasis & Rosacea practice, Neurodermatitis (ICD-10 L28.0) is stratified through contact/systemic trigger review [Neurodermatitis L28.0], pairing targeted symptom control with longitudinal Affected Body Surface in Neurodermatitis (L28.0: Area (BSA /) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Neurodermatitis (ICD-10 L28.0) is driven by keratinocyte hyperproliferation [Neurodermatitis L28.0]; specialists in Dermatology: Acne, Eczema, Psoriasis & Rosacea monitor Affected Body Surface in Neurodermatitis (L28.0: Area (BSA /) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Neurodermatitis (L28.0): persistent erythematous plaques, in Neurodermatitis (L28.0: scaly patches, pruritic)
- • Secondary Neurodermatitis clinical sign: compromised epidermal barrier in Neurodermatitis (L28.0: with dryness, fissuring,)
- • Symptom flares in Neurodermatitis correlating with 25-Hydroxy Vitamin D in Neurodermatitis (L28.0: & hs-CRP) deviation outside 25(OH)D 40–65 ng/mL (L28.0)
- • Functional skin & dermatology impact requiring contact/systemic trigger review [Neurodermatitis L28.0] evaluation (L28.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Neurodermatitis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L28.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Neurodermatitis (L28.0: & hs-CRP) | 25(OH)D 40–65 ng/mL (L28.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Neurodermatitis (L28.0: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L28.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Neurodermatitis (L28.0: ALT (if systemic) | Within baseline reference limits (L28.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Neurodermatitis
Treatment selection for Neurodermatitis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Neurodermatitis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Diflorasone diacetate: vasoconstrictor activity and clinical efficacy of a new: What a 384-Participant Study Found On the basis of additional vasoconstrictor assay results, a 0-05% concentration of the steroid in a cream vehicle containing 15% propylene glycol was developed for therapeutic evaluation. The Journal of international medical research • 1976-01-15 • Randomized Controlled Trial | N = 384 | 93/100 | PMID 800385 ↗ |
| Can This Approach Help? Inside the Latest Research on Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide In 2 pooled phase 3 studies, once-daily CAB gel was well tolerated and efficacious in children participants with acne, with over half achieving treatment success at week 12. Journal of drugs in dermatology : JDD • 2024-12-01 • Phase III Randomized Trial | N = 123 | 88/100 | PMID 39630680 ↗ |
| Can This Approach Help? Inside the Latest Research on Gold-standard blind paired comparison clinical trial of halcinonide and No side effects with either ointment were observed. Cutis • 1978-07-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 352631 ↗ |
| Can This Approach Help? Inside the Latest Research on Human chorionic gonadotrophin is a better luteal support than progesterone in We conclude that HCG is superior to i.m. Human reproduction (Oxford, England) • 1993-09-15 • Randomized Controlled Trial | N = 60 | 82/100 | PMID 8253920 ↗ |
Neurodermatitis Patient Community & “People Like Me” Threads
Filter Neurodermatitis community threads and patient logs by age, biological sex, dosage, and treatment duration.